Anti-hiv activity of liposomal nystatin and amphotericin b

Details Anti-hiv activity of liposomal nystatin and amphotericin b Anti-hiv activity of liposomal nystatin and amphotericin b

A - Human Necessities

61

K

A61K 9/127 (2006.01) A61K 47/24 (2006.01) A61K 47/28 (2006.01) A61K 31/71 (1990.01)

Patent

CA 2099772

ANTI-HIV ACTIVITY OF LIPOSOMAL NYSTATIN AND AMPHOTERICIN B ABSTRACT OF THE INVENTION A method is disclosed for inhibiting the replication of HIV-1 virus. The method includes the step of administering to a subject which is infected with HIV-1 a pharmaceutically effective amount of a liposomal composition which comprises at least one lipid and a polyene selected from nystatin and amphotericin B. Such liposomal compositions have been found to be selectively toxic for HIV-infected cells.The composition preferably comprises nystatin, dimyristoyl phosphatidyl choline, and dimyristoyl phosphatidyl glycerol, with the weight ratio of the latter two components being about 7:3.

Affiliated with

Also associated with

Rating

Anti-hiv activity of liposomal nystatin and amphotericin b does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Anti-hiv activity of liposomal nystatin and amphotericin b, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Anti-hiv activity of liposomal nystatin and amphotericin b will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFCA-PAI-O-1843963